Download Citation
Article Source:
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
Rivolo S,
Di Fusco M,
Polanco C,
Kang A,
Dhanda D,
et al.
(2021)
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
PLOS ONE 16(11): e0259251.
https://doi.org/10.1371/journal.pone.0259251